Ritter Pharmaceuticals (RTTR) Stock Price Down 5.1%

Ritter Pharmaceuticals Inc (NASDAQ:RTTR) shares traded down 5.1% during trading on Friday . The company traded as low as $0.80 and last traded at $0.93. 1,500 shares changed hands during trading, a decline of 99% from the average session volume of 101,750 shares. The stock had previously closed at $0.98.

A number of research analysts have recently commented on the company. HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Ritter Pharmaceuticals in a report on Wednesday, August 15th. ValuEngine lowered Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, October 29th. Finally, Zacks Investment Research raised Ritter Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, August 1st.

The stock has a market capitalization of $5.87 million, a P/E ratio of -0.18 and a beta of 1.21.

Ritter Pharmaceuticals (NASDAQ:RTTR) last announced its quarterly earnings data on Tuesday, August 14th. The biotechnology company reported ($0.71) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.56) by ($0.15). As a group, analysts predict that Ritter Pharmaceuticals Inc will post -2.97 earnings per share for the current year.

In related news, Director Matthew W. Foehr bought 19,751 shares of the business’s stock in a transaction that occurred on Friday, August 17th. The stock was acquired at an average price of $2.04 per share, for a total transaction of $40,292.04. Following the transaction, the director now directly owns 54,751 shares of the company’s stock, valued at $111,692.04. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 21.60% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: “Ritter Pharmaceuticals (RTTR) Stock Price Down 5.1%” was reported by WKRB News and is the property of of WKRB News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.wkrb13.com/2018/11/09/ritter-pharmaceuticals-rttr-stock-price-down-5-1.html.

Ritter Pharmaceuticals Company Profile (NASDAQ:RTTR)

Ritter Pharmaceuticals, Inc develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance.

Read More: Dividend Aristocrat Index

Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply